Cargando…
Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient
BACKGROUND: Erythropoietin-stimulating agents (ESAs) are used to treat anemia in patients with chronic kidney disease, enabling maintenance of stable hemoglobin levels and eliminating the need for multiple transfusions. Epoetin-beta pegol (C.E.R.A.) is a continuous erythropoietin receptor activator...
Autores principales: | Shingu, Yasuki, Nakata, Tomohiro, Sawai, Shinji, Tanaka, Hisaya, Asai, Osamu, Tamagaki, Keiichi, Nakatani, Kimihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362491/ https://www.ncbi.nlm.nih.gov/pubmed/32664894 http://dx.doi.org/10.1186/s12882-020-01934-2 |
Ejemplares similares
-
Pure red cell aplasia induced by epoetin zeta
por: Panichi, Vincenzo, et al.
Publicado: (2016) -
Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017) -
Pure red cell aplasia after treatment of renal anaemia with epoetin theta
por: Herrington, W., et al.
Publicado: (2013) -
Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia
por: Mahajan, S. A., et al.
Publicado: (2015) -
Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
por: Wu, Yunzhou, et al.
Publicado: (2020)